Research Publications and Clinical Trials
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial
Michael J Corley , Maya Watanabe , Alina P S Pang , Varun B Dwaraka , Ryan Smith , Wadzanai Samaneka , Sarah Henn , Sonal Munsiff , Maria Saumoy , Sara McCallum , Kathleen V Fitch , Sarah M Chu , Marissa R Diggs , Judith A Aberg , Carlos D Malvestutto , Carl J Fichtenbaum , Judith S Currier , Markella V Zanni , Pamela S Douglas , Michael T Lu , Alan L Landay , Kristine M Erlandson , Heather J Ribaudo , Steven K Grinspoon
In 99 US participants from the REPRIEVE trial, pitavastatin prevented an increase in the pace of biological aging—measured by DunedinPACE—over 24 months, while the placebo arm showed a significant rise (P = .049). These findings suggest statin therapy may counteract the accelerated epigenetic aging commonly seen in people living with HIV, supporting further investigation into statins as longevity interventions in this population.
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial
Michael J Corley , Maya Watanabe , Alina P S Pang , Varun B Dwaraka , Ryan Smith , Wadzanai Samaneka , Sarah Henn , Sonal Munsiff , Maria Saumoy , Sara McCallum , Kathleen V Fitch , Sarah M Chu , Marissa R Diggs , Judith A Aberg , Carlos D Malvestutto , Carl J Fichtenbaum , Judith S Currier , Markella V Zanni , Pamela S Douglas , Michael T Lu , Alan L Landay , Kristine M Erlandson , Heather J Ribaudo , Steven K Grinspoon
In 99 US participants from the REPRIEVE trial, pitavastatin prevented an increase in the pace of biological aging—measured by DunedinPACE—over 24 months, while the placebo arm showed a significant rise (P = .049). These findings suggest statin therapy may counteract the accelerated epigenetic aging commonly seen in people living with HIV, supporting further investigation into statins as longevity interventions in this population.
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial
Michael J Corley , Maya Watanabe , Alina P S Pang , Varun B Dwaraka , Ryan Smith , Wadzanai Samaneka , Sarah Henn , Sonal Munsiff , Maria Saumoy , Sara McCallum , Kathleen V Fitch , Sarah M Chu , Marissa R Diggs , Judith A Aberg , Carlos D Malvestutto , Carl J Fichtenbaum , Judith S Currier , Markella V Zanni , Pamela S Douglas , Michael T Lu , Alan L Landay , Kristine M Erlandson , Heather J Ribaudo , Steven K Grinspoon
In 99 US participants from the REPRIEVE trial, pitavastatin prevented an increase in the pace of biological aging—measured by DunedinPACE—over 24 months, while the placebo arm showed a significant rise (P = .049). These findings suggest statin therapy may counteract the accelerated epigenetic aging commonly seen in people living with HIV, supporting further investigation into statins as longevity interventions in this population.